TLSA Stoklara Genel Bakış Bir biyoteknoloji şirketi olan Tiziana Life Sciences Ltd, Amerika Birleşik Devletleri'nde onkoloji ve immünoloji alanlarında insan hastalıklarını tedavi edecek moleküllerin keşfi ve geliştirilmesine odaklanmaktadır. Daha fazla detay
Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Tiziana Life Sciences Ltd Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Tiziana Life Sciences Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$0.68 52 Haftanın En Yüksek Seviyesi US$1.74 52 Haftanın En Düşük Seviyesi US$0.41 Beta 0.25 1 Aylık Değişim -7.61% 3 Aylık Değişim -26.88% 1 Yıllık Değişim 31.94% 3 Yıllık Değişim -8.10% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -54.67%
Son Haberler & Güncellemeler
Tiziana Life Sciences Ltd Announces Positive Results in Treating Spinal Cord Injury with Nasal Anti-Cd3 Jan 24
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab Jan 23
Tiziana Life Sciences Ltd. Announces Findings on the Prolonged Benefits of its Nasal Anti-CD3 Monoclonal Antibody Jan 13
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis Dec 24
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab Dec 18
Tiziana Life Sciences Ltd Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional U.S. Medical Centers Dec 04 Daha fazla güncelleme görün
Tiziana Life Sciences Ltd Announces Positive Results in Treating Spinal Cord Injury with Nasal Anti-Cd3 Jan 24
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab Jan 23
Tiziana Life Sciences Ltd. Announces Findings on the Prolonged Benefits of its Nasal Anti-CD3 Monoclonal Antibody Jan 13
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis Dec 24
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab Dec 18
Tiziana Life Sciences Ltd Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional U.S. Medical Centers Dec 04
New minor risk - Shareholder dilution Dec 03
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study Oct 31 Tiziana Life Sciences Ltd has filed a Follow-on Equity Offering in the amount of $50 million. Oct 26
New minor risk - Market cap size Sep 04
Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes Aug 19
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule Aug 14
Insufficient new directors Jul 30
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis Jun 13
Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program Jun 08 Tiziana Life Sciences Ltd announced delayed 20-F filing May 01
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program Apr 24
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program Apr 23
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology Apr 20
New minor risk - Share price stability Apr 19
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology Apr 19
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients Jan 09
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation Jan 05
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis Dec 19
Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023 Dec 02
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis Dec 01
New minor risk - Financial data availability Nov 12
Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment Oct 19
Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab Oct 17
Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS) Oct 14
Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis Sep 27
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely? Sep 19
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023 Aug 24
New major risk - Share price stability Aug 16
Insufficient new directors Aug 01
Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer Jun 14
New minor risk - Market cap size Jun 08
Tiziana Life Sciences Ltd. Announces Reduction in Microglial Activation in Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis Jun 07
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate Jun 03
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely? Jan 16
Tiziana Life Sciences Announces IND Filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer Jan 05
Tiziana Life Sciences Ltd Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (Spms) After Eleven Months of Dosing with Intranasal Foralumab Jan 04
Tiziana Life Sciences Ltd Announces Completion of Prerequisite Pre-Clinical Safety Study Dec 16
Tiziana Life Sciences Ltd. Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirements Dec 15
Tiziana Life Sciences Ltd, Annual General Meeting, Dec 29, 2022 Dec 07
Tiziana Life Sciences Ltd Announces Publication of A Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T Cell Function and an Induced T Cell Regulatory Response in Human Subjects Nov 24
Less than half of directors are independent Nov 16
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (Cns) Nov 11
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for Its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients Nov 03
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in Its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients Oct 27
Tiziana Life Sciences Ltd. Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients Oct 13
Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy Oct 12
Tiziana chief medical officer further increases holdings in company Sep 23
Tiziana Life Sciences Ltd Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (Spms) After Six Months of Dosing with Intranasal Foralumab Sep 21
Tiziana Life Sciences Ltd(NasdaqGM:TLSA) dropped from S&P Global BMI Index Sep 19
Tiziana Life Sciences Announces Grant Received by the Brigham and Women’S Hospital to Explore the Use of Intranasal Anti-Cd3 Mab in Amyotrophic Lateral Sclerosis Sep 16
Tiziana Life Sciences executive chairman further raises stake in company Sep 16
Tiziana executive chairman raises stake in company again, buys more shares Aug 25
Tiziana Life Sciences discloses share purchase by executive chairman Aug 17
Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans? Aug 15
Less than half of directors are independent Jul 29
Tiziana Life Sciences Appoints Matthew W. Davis as Chief Medical Officer and Acting Chief Scientific Officer Jul 19 Tiziana Life Sciences Ltd Announces Resignation of Kunwar Shailubhai as Chief Scientific Officer and Board Director
Tiziana Life Sciences CEO Kunwar Shailubhai resigns Jul 15
Tiziana Life Sciences Receives Nasdaq Deficiency Notice Jun 20
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab Jun 09
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules May 26
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules May 25
Less than half of directors are independent Apr 27
Tiziana Life Sciences Announces FDA Grants Permission to Enroll Up to 8 Additional Secondary Progressive Multiple Sclerosis Patients in the Expanded Access Program with Intranasal Foralumab Apr 06
Tiziana Life Sciences Ltd Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, Fully Human Anti-Cd3 Monoclonal Antibody, in Patients with Crohn’s Disease Feb 05
Tiziana Life Sciences PLC (NasdaqGM:TLSA) announces an Equity Buyback for $5 million worth of its shares. Jan 25
Tiziana Life Sciences PLC Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis Jan 12
Less than half of directors are independent Oct 23 Hissedar Getirileri TLSA US Biotechs US Pazar 7D -0.7% -1.1% -0.3% 1Y 31.9% -2.3% 20.4%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: TLSA geçen yıl % -2.3 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: TLSA geçen yıl % 20.4 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı Is TLSA's price volatile compared to industry and market? TLSA volatility TLSA Average Weekly Movement 13.4% Biotechs Industry Average Movement 11.3% Market Average Movement 6.0% 10% most volatile stocks in US Market 18.5% 10% least volatile stocks in US Market 3.0%
İstikrarlı Hisse Senedi Fiyatı: TLSA hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: TLSA 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında Bir biyoteknoloji şirketi olan Tiziana Life Sciences Ltd, Amerika Birleşik Devletleri'nde onkoloji ve immünoloji alanlarında insan hastalıklarını tedavi etmek için moleküllerin keşfi ve geliştirilmesine odaklanmaktadır. Şirketin immünoloji alanındaki lider ürün adayı, Crohn, graft versus host, ülseratif kolit, multipl skleroz, tip-1 diyabet, inflamatuar bağırsak, sedef hastalığı ve romatoid artrit hastalıklarının tedavisi için bir insan anti-CD3 monoklonal antikoru (mAb) olan Foralumab'dır (TZLS-401). Ayrıca, çeşitli siklin bağımlı kinazların ve Src ailesinin oral yoldan biyoyararlanabilen küçük moleküllü geniş spektrumlu bir inhibitörü olan Milciclib'i (TZLS-201) ve enflamatuar ve onkoloji endikasyonlarının tedavisi için IL-6 reseptörünü hedefleyen tam insan mAb olan TZLS-501'i geliştirmektedir.
Daha fazla göster Tiziana Life Sciences Ltd Temel Bilgiler Özeti Tiziana Life Sciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? TLSA temel i̇stati̇sti̇kler Piyasa değeri US$70.14m Kazançlar(TTM ) -US$13.73m Gelir(TTM ) n/a
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) TLSA gelir tablosu (TTM ) Gelir US$0 Gelir Maliyeti US$0 Brüt Kâr US$0 Diğer Giderler US$13.73m Kazançlar -US$13.73m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/02/07 10:52 Gün Sonu Hisse Fiyatı 2025/02/07 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları Tiziana Life Sciences Ltd 6 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Mayank Mamtani B. Riley Securities, Inc. Robin Campbell Equity Development Limited Raghuram Selvaraju H.C. Wainwright & Co.
Göster 3 daha fazla analist 
